The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 4.25 — safe zoneOK
Where the revenue comes from
Fiscal 2025, as Entrada Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Recognition of upfront and milestone payments$20.3M
- Cost reimbursements$5.2M
Leadership changes
From Entrada Therapeutics, Inc.'s own filings, the day they're filed.
- Maha Radhakrishnan · director · appointmenteff. 2025-06-01
- Nathan J. Dowden · President · appointmenteff. 2024-01-01
- John F. Crowley · member · departureeff. 2023-12-05
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-10
- 8-K · Company announcement2026-05-19
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Entrada Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Entrada Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.